Bayer plans to acquire Perfuse Therapeutics for up to $2.45 billion, enhancing its presence in the ophthalmology sector. The deal includes a $300 million upfront payment and additional milestone payments linked to development and commercial success. This acquisition is part of Bayer’s strategy to expand its pipeline for eye disease treatments, reflecting ongoing consolidation in the pharmaceutical industry as companies invest in innovative therapies to drive growth.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://news.az/news/bayer-to-buy-perfuse-therapeutics-in-245-billion-deal
